CLYM
Climb Bio, Inc.Company Information
- Company Name
- Climb Bio, Inc.
- CIK
- CIK0001768446
- Category
- <br>Emerging growth company
- Ticker: Exchange
- CLYM: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- CLYM
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-01-05
- Last sale
- 2026-09-15
- Shares purchased (TTM)
- 108,573
- Shares sold (TTM)
- 157,215
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 54,293,122
- Shares outstanding
- 76,154,071
- Ownership
- 71.29%
Earnings Market Reaction
- Filing date
- 2026-08-06
- Price on filing date
- —
- 1-month reaction
- 4.07%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 44 | 8 | 36 | 26 | 23 | 29 | 87 | 146 | 223 | 105 | 93 | 57 | ||||||
| Marketable Securities Current | 139 | 101 | 65 | 61 | 62 | 69 | 64 | 47 | 0 | 0 | 14 | 50 | ||||||
| Prepaid Expense And Other Assets Current | 4 | 4 | 5 | 4 | 3 | 2 | 4 | 4 | 3 | 4 | 3 | 5 | ||||||
| Assets Current | 187 | 113 | 106 | 91 | 87 | 100 | 155 | 198 | 226 | 109 | 110 | 112 | ||||||
| Marketable Securities Noncurrent | 56 | 37 | 60 | 89 | 103 | 100 | 62 | 25 | - | - | 0 | - | ||||||
| Operating Lease Right Of Use Asset | 1 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Property Plant And Equipment Net | 1 | 0 | 0 | 0 | 0 | - | 0 | - | - | - | - | - | ||||||
| Other Assets Noncurrent | 2 | 2 | 2 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Assets | 246 | 152 | 168 | 182 | 192 | 201 | 217 | 222 | 226 | 109 | 110 | 113 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 1 | 1 | 2 | 0 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 1 | ||||||
| Accrued Liabilities And Other Liabilities | 4 | 3 | 4 | 4 | 5 | 6 | 4 | 3 | 3 | 3 | 2 | 2 | ||||||
| Operating Lease Liability Current | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Liabilities Current | 6 | 4 | 7 | 5 | 6 | 7 | 5 | 3 | 4 | 3 | 3 | 3 | ||||||
| Other Liabilities Noncurrent | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Operating Lease Liability Noncurrent | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Liabilities | 7 | 4 | 7 | 5 | 7 | 7 | 5 | 3 | 4 | 3 | 3 | 3 | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital Common Stock | 557 | 451 | 450 | 449 | 445 | 444 | 442 | 440 | 435 | 264 | 264 | 262 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0 | -0 | ||||||
| Retained Earnings Accumulated Deficit | -317 | -303 | -290 | -272 | -259 | -251 | -230 | -221 | -213 | -158 | -156 | -152 | ||||||
| Stockholders Equity | 240 | 148 | 160 | 177 | 186 | 193 | 212 | 219 | 222 | 106 | 108 | 110 | ||||||
| Liabilities And Stockholders Equity | 246 | 152 | 168 | 182 | 192 | 201 | 217 | 222 | 226 | 109 | 110 | 113 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 250 | 250 | 250 | 250 | 250 | 250 | 250 | 250 | 250 | 250 | 250 | 250 | ||||||
| Common Stock Shares Issued | 57 | 48 | 48 | 68 | 68 | 68 | 67 | 67 | 67 | 28 | 28 | 27 | ||||||
| Shares Outstanding | 57 | 48 | 48 | 68 | 68 | 68 | 67 | 67 | 67 | 28 | 28 | 27 | ||||||
| Income Tax Expense Benefit | - | - | - | - | - | - | - | 0 | - | - | - | 0 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialClimb Bio, Inc. (CLYM) — SEC Financial Statements & Analysis
Climb Bio, Inc. (CLYM) is a pharmaceutical preparations company, incorporated in DE. Climb Bio, Inc. trades on Nasdaq as: CLYM. Climb Bio, Inc. (CLYM)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06. Based on that filing, Climb Bio, Inc. carries a market cap of $993.05M, a P/E ratio of -17.23x, a P/B ratio of 4.15x, an enterprise value of $948.94M, and an EV/EBITDA multiple of -14.68x. On profitability, it posts a Return on Equity (ROE) of -27.10%, a Return on Assets (ROA) of -26.27%, and a Return on Invested Capital (ROIC) of -36.12%. Per share, it reports EPS of $-0.76, diluted EPS of $-0.76, free cash flow per share of $-0.70, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of 23.24% year-over-year and EPS growth of 9.37% year-over-year. On the balance sheet, it maintains a current ratio of 31.45x, a quick ratio of 30.86x, working capital of $180.70M, a debt-to-equity ratio of 0.03x, a debt ratio of 0.03, free cash flow of $-53.07M (TTM), and net debt of $-44.11M. Figures sourced from SEC EDGAR.
- Market Cap
- $993.05M
- P/E TTM
- -17.23x
- EPS TTM
- $-0.76
- P/B TTM
- 4.15x
- ROE TTM
- -27.10%
- ROA TTM
- -26.27%
- Debt To Equity
- 0.03x
- Free Cash Flow TTM
- $-53.07M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Climb Bio, Inc. in?
Climb Bio, Inc. (CLYM) operates in the Pharmaceutical Preparations industry.
What exchange does CLYM trade on?
Climb Bio, Inc. (CLYM) trades on the Nasdaq.
Where is Climb Bio, Inc. incorporated?
Climb Bio, Inc. is incorporated in DE.
When was Climb Bio, Inc. (CLYM)'s most recent SEC filing?
Climb Bio, Inc. (CLYM)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06.
What is CLYM's market cap?
Climb Bio, Inc. (CLYM) has a market capitalization of $993.05M as of 2026-06-30.
What is CLYM's EPS (earnings per share)?
Climb Bio, Inc. (CLYM)'s trailing twelve month EPS is $-0.76 as of 2026-06-30.
What is CLYM's ROE (return on equity)?
Climb Bio, Inc. (CLYM)'s trailing twelve month Return on Equity (ROE) is -27.10% as of 2026-06-30.
What is CLYM's ROA (return on assets)?
Climb Bio, Inc. (CLYM)'s trailing twelve month Return on Assets (ROA) is -26.27% as of 2026-06-30.
What is CLYM's ROIC (return on invested capital)?
Climb Bio, Inc. (CLYM)'s trailing twelve month Return on Invested Capital (ROIC) is -36.12% as of 2026-06-30.
What is CLYM's EV/EBITDA?
Climb Bio, Inc. (CLYM)'s trailing twelve month EV/EBITDA is -14.68x as of 2026-06-30.